文献类型：期刊文献

英文题名：Trimethyl Chitosan-Engineered Cod Skin Peptide Nanosystems Alleviate Behavioral and Cognitive Deficits in D-Galactose-Induced Alzheimer's Disease Model Mice

作者：Kong, Songzhi[1];Lv, Lijiao[1];Guo, Jiaqi[1];Lu, Guiping[1];Li, Dongdong[1];Zhou, Xin[1]

机构：[1]Guangdong Ocean Univ, Coll Chem & Environm Sci, Zhanjiang 524088, Peoples R China

年份：2025

卷号：23

期号：12

外文期刊名：MARINE DRUGS

收录：SCI-EXPANDED(收录号：WOS:001646999600001)、、Scopus(收录号：2-s2.0-105025734179)、WOS

基金：This research was funded by 2023 Key Scientific Research Platforms and Projects of Guangdong Provincial Universities-Special Program for Key Fields in Guangdong Provincial Universities (Biomedicine and Health) (Project No. 2023ZDZX2027), Basic and Applied Basic Research Foundation of Guangdong Province (Project No. 2023A1515110780) and the program for scientific research start-up funds of Guangdong Ocean University (Project No. 060302122312).

语种：英文

外文关键词：trimethyl chitosan nanoparticles; cod skin collagen peptides; Alzheimer's disease; neuroprotection

外文摘要：Alzheimer's disease (AD) is a common neurodegenerative disorder with limited effective treatments. Cod skin collagen peptides (CSCPs) have neuroprotective potential for AD but face poor bioavailability-due to gastrointestinal enzyme cleavage and hepatic first-pass metabolism-prompting this study to develop a nanodelivery system to enhance CSCPs' efficacy. Trimethyl chitosan (TMC)-based CSCP-loaded nanoparticles (CSCPs-NPs) were synthesized via ionic gelation, characterized for physicochemical properties, and tested in a D-galactose-induced AD mouse model (six groups: normal control, model, CSCPs low/high dose, blank NPs, CSCPs-NPs) using behavioral tests, histopathology, immunohistochemistry, and ELISA. CSCPs-NPs had a hydrodynamic diameter of 93.25 +/- 21.52 nm, polydispersity index of 0.18 +/- 0.13, 61.17% encapsulation efficiency, and sustained 24 h release. In AD mice, CSCPs-NPs significantly improved cognitive function and motor coordination, reduced hippocampal atrophy, preserved neurons, and mitigated oxidative stress, neuroinflammation, and apoptosis (upregulated Bcl-2, downregulated Bax)-effects matching high-dose free CSCPs. This TMC-based nanoformulation enhances CSCPs' bioavailability and provides a promising strategy for AD intervention.